Clinical concentrations of obeticholic acid were tested in an organotypic liver model. Transcriptomics reveal metabolic pathway effects beneficial in fatty liver disease. Changes predictive of lipoprotein abnormalities were also noted. Cytochrome P450 effects raise concern for potential drug-drug interactions.